Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma

Published:2016-11 Issue: Volume:62 Page:147-148
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Baxi Shrujal S.,Dunn Lara A.,Burtness Barbara A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference11 articles.

1. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases;Di Giacomo;Cancer Immunol, immunother: CII,2009

2. Evaluation of immune-related response criteria (irRC) in patients (pis) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475;Hodi;J Clin Oncol,2014

3. Long-term survival of ipilimumab-naive patients with advanced melanoma (Mel) treated with nivolumab (anti-Programmed Death-1; Anti-Pd-1; Bms-936558; Ono-4538) in a phase I trial;Hodi;Asia-Pac J Clin Oncol,2014

4. Pseudoprogression and immune-related response in solid tumors;Chiou;J Clin Oncol,2015

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria;Wolchok;Clin Cancer Res,2009

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging findings can’t mean everything in the era of immunotherapy: a case report and literature review;Immunotherapy;2024-02

2. Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report;Medicine;2023-08-04

3. Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma;Current Opinion in Oncology;2023-03-14

4. New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma;Vaccines;2022-06-01

5. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review;Frontiers in Nutrition;2022-03-25